High throughput RNA-seq analysis in human primary chondrocytes treated with cyproheptadine and IL-1β

Osteoarthritis is the most common joint disease. Controlling the complex pathogenesis is challenging, thus disease-modifying OA drugs (DMOADs) are not available. We identified cyproheptadine as a potential DMOAD candidate and performed bulk RNA-seq to determine its effects on the transcriptome in human primary chondrocytes in the absence or presence of IL-1β. Human primary chondrocytes were treated with DMSO (control), cyproheptadine, IL-1β or cyproheptadine + IL-1β (n=5 per group) and total RNA was extracted for bulk RNA-seq.